阿布昔替尼治疗中重度特应性皮炎随机临床试验
该3期双盲安慰剂对照试验纳入391例≥12岁中重度特应性皮炎患者,随机接受阿布昔替尼200mg、100mg或安慰剂治疗12周。结果显示两种剂量在IGA应答、EASI-75、PP-NRS应答及EASI-90上均显著优于安慰剂,不良事件发生率略高但严重不良事件少见。
要点
- 阿布昔替尼200mg和100mg每日一次治疗12周可显著改善中重度AD的皮损和瘙痒。
- 200mg组IGA应答率38.1%、EASI-75达61.0%,均显著高于安慰剂组。
- 200mg组报告血小板计数下降及提示血小板减少的实验室值,需监测。
核心结论
- 每日一次口服阿布昔替尼单药治疗对青少年和成人中重度特应性皮炎有效且耐受性良好。
研究设计与样本
- 3期双盲安慰剂对照平行组随机临床试验,纳入391例≥12岁中重度AD患者,来自13个国家115个中心。
- 患者按2:2:1随机接受阿布昔替尼200mg/d、100mg/d或安慰剂治疗12周。
主要发现
- 第12周IGA应答率:200mg组38.1%(59/155)、100mg组28.4%(44/155)、安慰剂组9.1%(7/77),P<.001。
- 第12周EASI-75应答率:200mg组61.0%(94/154)、100mg组44.5%(69/155)、安慰剂组10.4%(8/77),P<.001。
- 第12周PP-NRS应答估计比例:200mg组55.3%(95%CI 47.2%-63.5%)、100mg组45.2%(95%CI 37.1%-53.3%)、安慰剂组11.5%(95%CI 4.1%-19.0%),P<.001。
- 第12周EASI-90应答率:200mg组37.7%(58/154)、100mg组23.9%(37/155)、安慰剂组3.9%(3/77)。
- 不良事件发生率:200mg组65.8%(102例)、100mg组62.7%(99例)、安慰剂组53.8%(42例);严重不良事件分别为1.3%(2例)、3.2%(5例)、1.3%(1例)。
关键数值与推荐
- 共同主要终点为第12周IGA应答(清除[0]或几乎清除[1]且改善≥2级)和EASI-75应答。
- 关键次要终点包括第12周PP-NRS应答(改善≥4分),其他次要终点包括EASI-90应答。
临床怎么用
- 阿布昔替尼200mg或100mg每日一次可作为中重度AD且外用药物应答不足患者的单药治疗选择。
- 治疗期间需关注不良事件,200mg组报告血小板计数下降和提示血小板减少的实验室值。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Abrocitinib, an oral, once-daily Janus kinase 1 selective inhibitor, was effective and well tolerated in a phase 3 monotherapy trial of patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVE: To investigate the efficacy and safety of abrocitinib in adolescents and adults with moderate-to-severe AD in an identically designed trial. DESIGN, SETTING, AND PARTICIPANTS: This phase 3, double-blinded, placebo-controlled, parallel-group randomized clinical trial included patients 12 years or older with a clinical diagnosis of moderate-to-severe AD for at least 1 year and inadequate response to topical medications given for at least 4 weeks within 6 months. Patients were enrolled from 115 centers in Australia, Bulgaria, Canada, China, Czechia, Germany, Hungary, Japan, South Korea, Latvia, Poland, United Kingdom, and the United States from June 29, 2018, to August 13, 2019. Data were analyzed from September 13 to October 25, 2019. INTERVENTIONS: Patients were randomly assigned (2:2:1) to receive once-daily oral abrocitinib in 200- or 100-mg doses or placebo for 12 weeks. MAIN OUTCOMES AND MEASURES: The coprimary end points were the proportion of patients achieving Investigator Global Assessment (IGA) response (ie, clear [0] or almost clear [1], with improvement of ≥2 grades) and the proportion of patients achieving at least 75% improvement in Eczema Area and Severity Index score (EASI-75) at week 12. Key secondary end points included the proportion of patients achieving a Peak Pruritus Numerical Rating Scale (PP-NRS) response (ie, improvement of ≥4 points) at week 12. Other secondary end points included the proportion of patients achieving at least 90% improvement in EASI score (EASI-90). Safety was assessed via adverse events and laboratory monitoring. RESULTS: A total of 391 patients (229 male [58.6%]; mean [SD] age, 35.1 [15.1] years) were included in the analysis; of these, 155 received abrocitinib, 200 mg/d; 158, abrocitinib, 100 mg/d; and 78, placebo. Among patients with available data at week 12, greater proportions of patients in the 200- and 100-mg abrocitinib groups vs the placebo group achieved IGA (59 of 155 [38.1%] and 44 of 155 [28.4%] vs 7 of 77 [9.1%]; P < .001) and EASI-75 (94 of 154 [61.0%] and 69 of 155 [44.5%] vs 8 of 77 [10.4%]; P < .001), greater estimated proportions achieved PP-NRS (55.3% [95% CI, 47.2%-63.5%] and 45.2% [95% CI, 37.1%-53.3%] vs 11.5% [95% CI, 4.1%-19.0%]; P < .001), and/or greater proportions achieved EASI-90 (58 of 154 [37.7%] and 37 of 155 [23.9%] vs 3 of 77 [3.9%]) responses. Adverse events were reported for 102 patients (65.8%) in the 200-mg group, 99 (62.7%) in the 100-mg group, and 42 (53.8%) in the placebo group; serious adverse events were reported for 2 patients (1.3%) in the 200-mg group, 5 (3.2%) in the 100-mg group, and 1 (1.3%) in the placebo group. Decreases in platelet count (2 [1.3%]) and laboratory values indicating thrombocytopenia (5 [3.2%]) were reported in the 200-mg group. CONCLUSIONS AND RELEVANCE: Monotherapy with once-daily oral abrocitinib was effective and well tolerated in adolescents and adults with moderate-to-severe AD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03575871.
引用
- Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2020. PMID: 32492087. doi:10.1001/jamadermatol.2020.1406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。